Commission Decision
of 12 October 2009
authorising the placing on the market of a lipid extract from Antarctic Krill Euphausia superba as a novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council
(notified under document C(2009) 7647)
(Only the English text is authentic)
(2009/752/EC)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,
Having regard to the Treaty establishing the European Community,
Having regard to Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and novel food ingredients, and in particular Article 7 thereof,
OJ L 43, 14.2.1997, p. 1.
Whereas:
(1) On 29 September 2006 the company Neptune Technologies & Bioressources Inc. made a request to the competent authorities of Finland to place a lipid extract from Antarctic Krill Euphausia superba on the market as a novel food ingredient.
(2) On 29 January 2007 the competent food assessment body of Finland issued its initial assessment report. In that report it came to the conclusion that the use of the lipid extract from Antarctic Krill Euphausia superba as a food ingredient was acceptable.
(3) The Commission forwarded the initial assessment report to all Member States on 19 February 2007.
(4) Within the 60-day period laid down in Article 6(4) of Regulation (EC) No 258/97 reasoned objections to the marketing of the product were raised in accordance with that provision.
(5) Therefore the European Food Safety Authority (EFSA) was consulted on 31 January 2008.
(6) In the Scientific Opinion of the Panel on dietetic products nutrition and allergies on a request from the European Commission on the safety of lipid extract from Euphausia superba as food ingredient, the panel came to the conclusion that the lipid extract from Antarctic Krill Euphausia superba was safe under the proposed conditions of use.
(7) On the basis of the initial assessment report, it is established that the lipid extract from Antarctic Krill Euphausia superba complies with the criteria laid down in Article 3(1) of the Regulation.
(8) The measures provided for in this Decision are in accordance with the opinion of the Standing Committee on the Food Chain and Animal Health,
HAS ADOPTED THIS DECISION:

Article 1 Lipid extract from Antarctic Krill Euphausia superba as specified in Annex I, may be placed on the market in the Community as a novel food ingredient for the uses and at the maximum levels as listed in Annex II.
Article 2 The designation ‘lipid extract from the crustacean Antarctic Krill Euphausia superba’ shall be displayed on the labelling of the product as such or in the list of ingredients of foodstuffs containing it.
Article 3 This Decision is addressed to Neptune Technologies & Bioressources Inc., 225 Promenade du Centropolis, Suite 200, Laval, Quebec H7T 0B3, Canada.
Done at Brussels, 12 October 2009.
For the Commission
Androulla Vassiliou
Member of the Commission

ANNEX I SPECIFICATION OF LIPID EXTRACT FROM ANTARCTIC KRILL EUPHAUSIA SUPERBA

Description
To produce lipid extract from Antarctic Krill Euphausia superba deep-frozen Antarctic krill is crushed and subjected to an extraction with acetone. Proteins and krill material are removed from the lipid extract by filtration. The acetone and residual water are removed by evaporation.
Test	Specification
Saponification value	Not more than 185 mg KOH/g
Peroxide value (PV)	Not more than 0,2 meq O2/kg oil
Moisture and volatiles	Not more than 0,9 %
Phospholipids	Not more than 50 %
Trans-fatty acids	Not more than 1 %
EPA (eicosapentaenoic acid)	Not less than 15 %
DHA (docosahexaenoic acid)	Not less than 7 %

ANNEX II USES OF LIPID EXTRACT FROM ANTARCTIC KRILL EUPHAUSIA SUPERBA
Use group	Maximum content of combined DHA and EPA
Dairy products except milk-based drinks	200 mg/100 g or for cheese products 600 mg/100 g
Dairy analogues except drinks	200 mg/100 g or for analogues to cheese products 600 mg/100 g
Spreadable fat and dressings	600 mg/100 g
Breakfast cereals	500 mg/100 g
Food supplements	200 mg per daily dose as recommended by the manufacturer
Dietary foods for special medical purposes	In accordance with the particular nutritional requirements of the persons for whom the products are intended
Foods intended for use in energy restricted diets for weight reduction	200 mg/meal replacement